• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips 200 Points; Nike Shares Fall After Q3 Results

    3/22/24 12:18:41 PM ET
    $BIOL
    $CUTR
    $ISPR
    $NKE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BIOL alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points.

    The Dow traded down 0.54% to 39,565.50 while the NASDAQ rose 0.04% to 16,408.74. The S&P 500 also fell, dropping, 0.14% to 5,233.98.

    Check This Out: These 3 Risk Off Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Communication services shares jumped by 0.7% on Friday.

    In trading on Friday, consumer discretionary shares fell by 0.9%.

     

    Top Headline

     

    Shares of Nike Inc (NYSE:NKE) fell more than 8% on Friday after the company reported results for its third quarter.

    Nike reported third-quarter revenue of $12.429 billion, which was up slightly year-over-year. The revenue total beat a Street consensus estimate of $12.281 billion according to data from Benzinga Pro. Nike reported adjusted earnings per share of 98 cents, which beat a Street consensus estimate of 74 cents per share.

     

    Equities Trading UP

     

    Summit Midstream Partners, LP (NYSE:SMLP) shares shot up 35% to $26.20 after the company announced the sale of its Utica position for $625 million.

    Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) got a boost, surging 36% to $9.56 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD.

    BIOLASE, Inc. (NASDAQ:BIOL) shares were also up, gaining 43% to $0.2150 after the company reported better-than-expected fourth-quarter earnings results.

     

    Equities Trading DOWN

     

    Cutera, Inc. (NASDAQ:CUTR) shares dropped 32% to $1.5750 after the company reported worse-than-expected fourth quarter adjusted EPS results.

    Shares of Sintx Technologies, Inc. (NASDAQ:SINT) were down 28% to $0.0980 after the company announced a proposed public offering of common stock.

    Ispire Technology Inc. (NASDAQ:ISPR) was down, falling 27% to $5.95 after the company announced the pricing of its public offering of 2.05 million shares of common stock at $6.00 per share.

    Also Check This Out: Top 3 Materials Stocks That Could Blast Off In Q1

     

    Commodities

     

    In commodity news, oil traded down 0.4% to $80.77 while gold traded down 0.4% at $2,175.60.

    Silver traded down 0.4% to $24.905 on Friday, while copper fell 1.2% to $4.0080.

     

    Euro zone

     

    European shares were mixed today. The eurozone’s STOXX 600 fell 0.05%, London’s FTSE 100 jumped 0.64% while Spain’s IBEX 35 Index rose 0.55% The German DAX rose 0.08% French CAC 40 fell 0.46% while Italy’s FTSE MIB Index fell 0.07%.

    The Ifo Business Climate indicator for Germany climbed to 87.8 in March from February's revised reading of 85.7. German import prices declined 5.9% year-over-year in January.

    Retail sales volumes in the UK came in unchanged for February, while UK’s GfK Consumer Confidence indicator came in flat at -21 in March.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 gaining 0.18%, Hong Kong’s Hang Seng Index falling 2.16%, China’s Shanghai Composite Index falling 0.95% and India’s S&P BSE Sensex gaining 0.26%.

    Foreign direct investment into China dipped by 19.9% year-over-year to CNY 215.1 billion during the first two months of the year. The annual inflation rate in Japan accelerated to 2.8% in February from 2.2% a month ago.

     

    Economics

     

    The Baker Hughes rig count report for the recent week will be released at 1:00 p.m. ET.


    Now Read This: Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying

     

    Get the next $BIOL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOL
    $CUTR
    $ISPR
    $NKE

    CompanyDatePrice TargetRatingAnalyst
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    Nike Inc.
    $NKE
    12/19/2025$75.00 → $72.00Market Perform
    Telsey Advisory Group
    Nike Inc.
    $NKE
    12/19/2025$78.00 → $68.00Buy
    Needham
    Nike Inc.
    $NKE
    12/10/2025$77.00Buy
    Guggenheim
    Nike Inc.
    $NKE
    11/13/2025$75.00Equal Weight → Overweight
    Wells Fargo
    Nike Inc.
    $NKE
    10/15/2025$100.00Buy
    BTIG Research
    Nike Inc.
    $NKE
    10/2/2025$90.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $BIOL
    $CUTR
    $ISPR
    $NKE
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    2/11/26 5:00:40 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outlook Therapeutics Inc.

    SCHEDULE 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    2/5/26 11:48:52 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP: Chief Legal Officer Leinwand Robert sold $565,021 worth of Class B Common Stock (9,065 units at $62.33), decreasing direct ownership by 13% to 61,662 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/13/26 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Chairman Emeritus Knight Philip H gifted 4,500,000 units of Class B Common Stock and received a gift of 4,500,000 units of Class B Common Stock, decreasing direct ownership by 35% to 8,335,687 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/13/26 4:23:29 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    EVP: Chief Legal Officer Leinwand Robert covered exercise/tax liability with 4,647 units of Class B Common Stock, decreasing direct ownership by 6% to 70,727 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/12/26 4:16:13 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

    ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company's Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). The CRL identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended

    2/11/26 8:45:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Swan Robert Holmes bought $500,080 worth of Class B Common Stock (8,691 units at $57.54), increasing direct ownership by 25% to 43,293 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:21:15 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on NIKE

    Deutsche Bank initiated coverage of NIKE with a rating of Hold

    1/8/26 10:59:22 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE downgraded by Needham

    Needham downgraded NIKE from Buy to Hold

    1/8/26 8:41:20 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on NIKE with a new price target

    Telsey Advisory Group reiterated coverage of NIKE with a rating of Market Perform and set a new price target of $72.00 from $75.00 previously

    12/19/25 7:55:36 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vuori Appoints Andrew Campion to Board of Directors

    The addition of the industry leader reinforces the brand's continued momentum and further fuels its strategic growth priorities Vuori, the performance and lifestyle brand known for its coastal California-inspired style, today announced the appointment of Andrew Campion to its Board of Directors and a member of its Audit Committee. For over 17 years, Andy served in executive leadership roles at Nike Inc. (NYSE:NKE), including as Chief Operating Officer, Chief Financial Officer, and head of global strategy. Prior to Nike, Campion was with The Walt Disney Company (NYSE:DIS), serving as its Senior Vice President of Corporate Development. Currently, Andy is the Chairman and CEO of Unrivaled

    9/15/25 6:00:00 AM ET
    $DIS
    $NKE
    $SBUX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Shoe Manufacturing
    Restaurants

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Financials

    Live finance-specific insights

    View All

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $BIOL
    $CUTR
    $ISPR
    $NKE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cutera Inc.

    SC 13G/A - CUTERA INC (0001162461) (Subject)

    11/12/24 2:37:12 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care